NASDAQ:CERO CERo Therapeutics (CERO) Stock Price, News & Analysis $0.01 +0.00 (+4.00%) As of 02:49 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsSEC Filings About CERo Therapeutics Stock (NASDAQ:CERO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CERo Therapeutics alerts:Sign Up Key Stats Today's Range$0.01▼$0.011050-Day Range$0.0080▼$0.016752-Week Range$0.01▼$5.72Volume401,180 shsAverage Volume675,496 shsMarket Capitalization$744.96 thousandP/E RatioN/ADividend YieldN/APrice Target$30.00Consensus RatingReduce Company Overview CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California. Read More CERo Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks19th Percentile Overall ScoreCERO MarketRank™: CERo Therapeutics scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.8 / 5Analyst RatingReduce Consensus RatingCERo Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialCERo Therapeutics has a consensus price target of $30.00, representing about 288,361.5% upside from its current price of $0.01.Amount of Analyst CoverageCERo Therapeutics has received no research coverage in the past 90 days.Read more about CERo Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of CERo Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CERo Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CERO. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCERo Therapeutics does not currently pay a dividend.Dividend GrowthCERo Therapeutics does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A Search Interest3 people have searched for CERO on MarketBeat in the last 30 days. MarketBeat Follows1 people have added CERo Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CERo Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders0.36% of the stock of CERo Therapeutics is held by insiders.Percentage Held by Institutions29.64% of the stock of CERo Therapeutics is held by institutions.Read more about CERo Therapeutics' insider trading history. Receive CERO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CERo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CERO Stock News HeadlinesCERo Therapeutics Holdings Secures New Consolidated Financing FacilityAugust 31, 2026 | tipranks.comSRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of ...August 31, 2026 | markets.businessinsider.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.September 11 at 1:00 AM | InvestorPlace (Ad)CERo Therapeutics Expands Convertible Debt Financing ArrangementJuly 17, 2026 | tipranks.comNasdaq, Inc.: Delisting of Securities from The Nasdaq Stock MarketJuly 11, 2026 | finanznachrichten.deCERo Therapeutics Holdings, Inc. Common Stock (CERO)June 25, 2026 | nasdaq.comCERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following TreatmentJune 15, 2026 | globenewswire.comCERo Therapeutics Raises Funding via Convertible Note FinancingMay 29, 2026 | tipranks.comSee More Headlines CERO Stock Analysis - Frequently Asked Questions How have CERO shares performed this year? CERo Therapeutics' stock was trading at $0.0670 at the start of the year. Since then, CERO shares have decreased by 84.5% and is now trading at $0.0104. How were CERo Therapeutics' earnings last quarter? CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) posted its quarterly earnings results on Friday, August, 22nd. The company reported ($61.71) EPS for the quarter, topping analysts' consensus estimates of ($70.23) by $8.52. When did CERo Therapeutics' stock split? CERo Therapeutics's stock reverse split before market open on Friday, June 13th 2025.The 1-20 reverse split was announced on Wednesday, June 11th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 12th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of CERo Therapeutics? Shares of CERO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CERo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CERo Therapeutics investors own include Lithium Americas (LAC), NVIDIA (NVDA), Maxeon Solar Technologies (MAXN), ARM (ARM), AST SpaceMobile (ASTS) and BigBear.ai (BBAI). Company Calendar Last Earnings8/22/2025Today9/11/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CERO Previous SymbolNASDAQ:CERO CIK1870404 Webwww.cero.bio Phone215-731-9450FaxN/AEmployees8Year FoundedN/APrice Target and Rating Average Price Target for CERo Therapeutics$30.00 High Price Target$30.00 Low Price Target$30.00 Potential Upside/Downside+288,361.5%Consensus RatingReduce Rating Score (0-4)1.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($9.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.30 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-209.40% Debt Debt-to-Equity RatioN/A Current Ratio0.56 Quick Ratio0.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($41.98) per share Price / Book0.00Miscellaneous Outstanding Shares71,631,000Free Float1,052,000Market Cap$744.96 thousand OptionableN/A Beta0.19 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:CERO) was last updated on 9/11/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CERo Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CERo Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
